Rare cancers remain underserved by precision oncology. In this #Comment, the authors propose that systematic, variant-level pharmacological mapping of approved kinase inhibitors can transform this gap into an opportunity for scalable drug repurposing.
š š
Rare cancers remain underserved by precision oncology, in part because many oncogenic variants lack matched therapies despite a growing arsenal of targeted drugs. In this Comment, the authors propose that systematic, variant-level pharmacological mapping of approved kinase inhibitors can transform this gap into an opportunity for scalable drug repurposing.
